Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Athena will employ its successful history of securing government contracts, spearheading such initiativesJACKSON CENTER, PA / ACCESSWIRE / January 9,...
Addiction
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
Recovery Delivered Expands Services to Accept Medicaid in Ohio for Online Suboxone to Treat Opioid Addiction
Seeing a Suboxone doctor in Ohio just became much more affordable. Patients can now use their Ohio Medicaid to cover...
Clearview Treatment Programs Certified by PsychArmor as a ‘Veteran Ready’ Organization
BRENTWOOD, TN / ACCESSWIRE / January 4, 2024 / Odyssey Behavioral Healthcare, a leading provider of mental health, addiction, and...
Introducing PillSafe(R), the New ‘Smart’ Pill Bottle for Prescription Medication
PillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse,...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE...
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and...
Corporate Governance at Alkermes
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / AlkermesOriginally published in Alkermes September 2023 Corporate Responsibility ReportBoard of DirectorsOur...
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents...
Optimind Pharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider...
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
The Newly Institute Reports Its Annual General and Special Meeting Voting Results and Provides an Operational Update
Calgary, Alberta--(Newsfile Corp. - December 18, 2023) - The Newly Institute ("Newly" or the "Company") is pleased to report the...
Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL
Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,...
Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions
VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing...
Revive Recovery and Detox Services Clarifies NO AFFILIATION With Revive Premier Treatment Center
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / Revive Recovery and Detox Services, an addiction treatment center located...
Silver Pines Treatment Center Achieves PsychArmor Certification as a ‘Veteran Ready’ Organization
BRENTWOOD, TN / ACCESSWIRE / December 5, 2023 / Odyssey Behavioral Healthcare, a leading provider of addiction, mental health, and...
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)...
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential...
Intrepid Recovery Center Unveils Innovative Partial Hospitalization Program (PHP) in West Palm Beach, Florida
Intrepid Recovery Center's Founder, John Nash Pakel, Champions the Next Phase in Addiction Treatment with the Introduction of PHP -...
BayMark Releases Whitepaper: 2023 Nationwide Opioid Use Disorder Treatment Outcomes Report
BayMark's Study Demonstrates the Path to More Successful Opioid Use Disorder TreatmentLEWISVILLE, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- BayMark,...